Drug Trial Radar · NCT04819464
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 25, 2021
Primary completion
Aug 18, 2024
Study completion Aug 18, 2024
Sponsor
- Lead sponsor
- Viatris Innovation GmbHIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, single-dose, phase 1 study, to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of cenerimod (ACT-334441).
Conditions
- Healthy
- Hepatic Impairment
Interventions
CenerimodDrug
A single oral dose of 0.5 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curves (AUC0-t): cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
- Area under the plasma concentration-time curve from zero to infinity (AUC0-inf): cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
- Maximum plasma concentration (Cmax): cenerimod.Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
- Time to reach Cmax (tmax): cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
- Terminal half-life (t½): cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
- Plasma protein binding of cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
- Apparent clearance (CL/F) of cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
- Apparent volume of distribution (Vz/F) of cenerimodTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
CRU Hungary
Kistarcsa, Hungary
BlueClinical Phase 1 Hospital de Prelado
Porto, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.